Cancer in Panama

IARC estimates 9,417 new cancer cases and 3,971 cancer deaths in Panama in 2024; the commonest new cancers are prostate, breast and colorectum. This page is assembled automatically from OnCo's data: 19 trials with a site there, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

9,417

all cancers

Deaths

3,971

all cancers

Incidence rate

158.2

per 100,000, age-standardised

Mortality rate

66.1

per 100,000, age-standardised

Cumulative risk

14.2%

of a cancer by age 74

Population

4,515,581

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	1,780	58.5	Prostate cancer
Breast	1,118	38.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	851	14.2	Colorectal cancer
Stomach	621	10.5	Gastric & gastro-oesophageal junction cancer
Thyroid	618	11.1	Thyroid cancer
Cervix uteri	436	15.9	Cervical cancer
Trachea, bronchus and lung	369	5.9	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Corpus uteri	312	11.4	Endometrial cancer
Leukaemia	296	5.5	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Liver and intrahepatic bile ducts	251	4.1	Hepatocellular carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Colorectum	418	6.9	Colorectal cancer
Prostate	411	13.7	Prostate cancer
Stomach	390	6.5	Gastric & gastro-oesophageal junction cancer
Breast	330	11.1	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	291	4.7	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Cervix uteri	232	8.1	Cervical cancer
Liver and intrahepatic bile ducts	213	3.4	Hepatocellular carcinoma
Leukaemia	184	3.4	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Pancreas	155	2.5	Pancreatic ductal adenocarcinoma
Non-Hodgkin lymphoma	116	2.0	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma

Incidence: method 3c, national mortality estimates applied to model-based mortality-to-incidence ratios (registry survival data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Panama”, in Central America (Latin America and the Caribbean), Very High HDI, upper middle income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

19 trials in OnCo · 4 recruiting overall

19 trials

Trial			Lead sponsor
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) NCT06796907	Phase 1/2	Recruiting	GlaxoSmithKline	82	2026-10-02
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) NCT07286331	Phase 3	Recruiting	GlaxoSmithKline	48	2026-10-02
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) NCT06885034	Phase 1/2	Recruiting	GlaxoSmithKline	85	2026-08-03
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer NCT05855200	Phase 3	Recruiting	GlaxoSmithKline	266	2026-01-23
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L NCT06687369	Phase 3	Active not recruiting	mAbxience Research S.L.	173	2026-09-10
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552	Phase 2/3	Active not recruiting	Hoffmann-La Roche	161	2026-09-03
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612	Phase 2	Active not recruiting	Genentech, Inc.	179	2026-08-28
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax NCT01081951	Phase 2	Active not recruiting	AstraZeneca	53	2026-08-05
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) NCT06472076	Phase 3	Active not recruiting	GlaxoSmithKline	108	2026-07-21
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors NCT06077877	Phase 1/2	Active not recruiting	GlaxoSmithKline	11	2026-04-24
APHINITY NCT01358877	Phase 3	Completed	Hoffmann-La Roche	546	2025-11-28
KATHERINE NCT01772472	Phase 3	Completed	Hoffmann-La Roche	268	2025-07-22
IMpassion130 NCT02425891	Phase 3	Completed	Hoffmann-La Roche	247	2022-07-19
OAK NCT02008227	Phase 3	Completed	Hoffmann-La Roche	208	2019-12-20
GOYA NCT01287741	Phase 3	Terminated	Hoffmann-La Roche	235	2019-04-12
GATSBY NCT01641939	Phase 2/3	Terminated	Hoffmann-La Roche	148	2017-05-12
Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer NCT01875393	Phase 3	Completed	Steba Biotech S.A.	3	2016-04-19
10TASQ10 NCT01234311	Phase 3	Completed	Active Biotech AB	204	2015-10-21
ToGA NCT01041404	Phase 3	Completed	Hoffmann-La Roche	142	2014-11-05

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Panama, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Panama is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

OnCo holds no institution, company or person in Panama.

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Panama is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Panama's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Panama, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Panama's own sources.

Panama is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/pa.json; every country: /api/v1/countries.json.